Imagine a tiny tool that gently disrupts a damaged vein wall to trick the body into thinking it needs to heal a wound. This process naturally closes the problematic vein, stopping the blood pooling that causes painful leg sores. It replaces bulky, wasteful bandages with a one-time internal fix.
Chronic venous disease affects 60% of adults over 50, leading to venous leg ulcers that are poorly treated by compression bandages. This creates a massive financial burden of €33.4 billion annually across Europe and the US.
A minimally invasive medical device that disrupts vein walls to trigger the body's natural healing response to close targeted veins.
If you are a vascular surgery equipment provider dealing with the high recurrence rates of traditional treatments — this project developed a device that mimics the body's natural healing response to close targeted veins. This provides a more effective alternative for the 60% of adults over 50 affected by chronic venous disease.
If you are a private clinic network dealing with the €33.4 billion annual cost of managing venous disease — this project developed a minimally invasive treatment for venous leg ulcers. It reduces the need for ineffective compression bandaging and improves patient outcomes.
If you are a catheter technology developer dealing with the need for better vein-closure mechanisms — this project developed a vein wall disruption technology. It allows for the treatment of varicose veins and ulcers without harmful side effects.
Based on available project data, the specific unit price or cost of the device is not disclosed, although the project received an EU contribution of EUR 2,497,614.
Based on available project data, the project focused on refining commercial and regulatory strategies for European and US markets, suggesting it is moving toward scale, but specific manufacturing capacity is not listed.
Based on available project data, the project is led by InVera Medical Limited, but specific patent numbers or licensing terms are not provided in the summary.
The project included work to refine regulatory strategies for the European and US markets aligned with a clinical regulatory study.
The project period ran from 2022-10-01 to 2024-09-30, with activities focused on preparing for engagement with investors and regulatory alignment.
The project is managed by a single-partner consortium consisting of one SME, InVera Medical Limited from Ireland. This 100% industry ratio indicates a highly commercial-driven project focused on rapid translation to market rather than academic research.
Contact InVera Medical Limited in Ireland
Contact us to explore licensing opportunities for this vein-closure technology.
